Aprea Therapeutics Showcases Cutting-Edge Oncology Research
Aprea Therapeutics, Inc. (NASDAQ: APRE) has recently announced exciting developments regarding its participation in an important oncology symposium. The company, known for its focus on precision oncology through the innovative approach of synthetic lethality, revealed that four of its abstracts have been accepted for poster presentations at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Event Details
This distinguished conference will be held in Barcelona and is set to take place between October 23 and 25. It serves as a significant platform for oncologists and researchers from around the world to exchange valuable insights and breakthroughs in cancer treatment.
Poster Presentations
Oren Gilad, Ph.D., the President and CEO of Aprea, expressed enthusiasm for the opportunity to highlight the company's ongoing advancements in its clinical pipeline. Two key clinical-stage inhibitors will be showcased:
- APR-1051: This WEE1 inhibitor aims at improving safety and preliminary efficacy for patients with cancer-associated gene alterations.
- ATRN-119: A novel macrocyclic ATR inhibitor currently being evaluated for patients with advanced solid malignancies.
Key Poster Sessions
The detailed schedule for the poster presentations is as follows:
Poster 1:
- Title: Safety and Preliminary Efficacy of APR-1051
- Session Date/Time: Wednesday, October 23rd, 12:00 - 19:00 CET
- Location: Exhibition Hall
- Poster #: 77
Poster 2:
- Title: ATRN-119 in Patients with Advanced Solid Malignancies
- Session Date/Time: Friday, October 25th, 09:00 - 15:00 CET
- Location: Exhibition Hall
- Poster #: 348
In addition to the clinical presentations, Aprea will also share preclinical findings that highlight its innovative approach to overcoming challenges in treating certain cancers.
Additional Research Highlights
Aprea's preclinical poster presentations feature:
- The novel WEE1 inhibitor APR-1051: Demonstrating minimal off-target effects on critical proteins and showcasing favorable characteristics in animal models.
- Development of Macrocyclic ATR inhibitors: Focusing on the advancement of a pioneering series of inhibitors designed specifically for cancer treatment.
These findings reaffirm Aprea’s commitment to advancing cancer care and its strategic focus on precision medicine.
Future Prospects for Aprea
Aprea Therapeutics continues to pave its way in the oncology landscape with its innovative research and development programs. The company is determined to translate its promising preclinical research into effective clinical applications. Geared towards not just improving patient outcomes but also enhancing the understanding of cancer mechanisms, Aprea's work remains at the forefront of cancer therapy advances.
Availability of Research Materials
Following the completion of the symposium, copies of the poster presentations will be made accessible on the Investor Resources page of Aprea's corporate website. This transparency provides stakeholders with insights into the company's research advancements and ongoing initiatives.
Frequently Asked Questions
What is the significance of the EORTC-NCI-AACR Symposium?
The symposium is a major event for oncology research where experts share innovations and advancements in cancer treatment.
What are the main focuses of Aprea Therapeutics?
Aprea is focused on precision oncology, developing therapies that utilize the concept of synthetic lethality to treat cancer.
What clinical candidates will Aprea present at the symposium?
Aprea will present two clinical-stage candidates: APR-1051 and ATRN-119.
Where can I find the research presented by Aprea?
Research materials will be available on the Investor Resources page of Aprea Therapeutics’ website after the symposium.
How does Aprea aim to impact cancer treatment?
Aprea is dedicated to developing innovative therapies that improve the efficacy and safety of cancer treatment options for patients.
